← Leaderboards
Brenda B. Diergaarde
University Of Pittsburgh At Pittsburgh
$2,598,011
Attributed
$6,221,633
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $817K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,221,633 · 3
By mechanism
R01$5,435,433 · 2
P50$786,200 · 1
Top collaborators
- Paul Joseph Brennan6 shared
- David N Hayes6 shared
- Theresa L. Whiteside4 shared
- Dan Paul Zandberg4 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Jennifer R Grandis$109,711,044
- Stephen Y Lai$10,561,066
- Theresa L. Whiteside$29,550,469
- Saleem A. Khan$7,070,061
- Yu Leo Lei$8,848,025
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingHead And Neck CancerHead And Neck Squamous Cell CarcinomaMalignant NeoplasmsCancer RiskCharacteristicsVariantMediatingClinically RelevantTumorSmokingAffectGenesReportingScreeningBiological MarkersHuman PapillomavirusDisease OutcomeDiagnosticDisorder RiskAnatomyAmericanDna Sequence AlterationBiological
Grant awards (14)
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$700,037
R01 · FY2025 · DE
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$686,036
R01 · FY2024 · DE
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$130,976
R01 · FY2024 · DE
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$640,719
R01 · FY2023 · DE
The role of germline and somatic DNA mutations in oral and oropharyngeal cancers$706,129
R01 · FY2021 · DE
The role of germline and somatic DNA mutations in oral and oropharyngeal cancers$613,147
R01 · FY2020 · DE
The role of germline and somatic DNA mutations in oral and oropharyngeal cancers$46,718
R01 · FY2020 · DE
The role of germline and somatic DNA mutations in oral and oropharyngeal cancers$631,228
R01 · FY2019 · DE
The role of germline and somatic DNA mutations in oral and oropharyngeal cancers$630,189
R01 · FY2018 · DE
The role of germline and somatic DNA mutations in oral and oropharyngeal cancers$650,254
R01 · FY2017 · DE
Vitamin D3 Modulation of Inflammation and Lung Cancer Risk$195,729
P50 · FY2015 · CA · contact PI
Vitamin D3 Modulation of Inflammation and Lung Cancer Risk$15,098
P50 · FY2014 · CA · contact PI
Vitamin D3 Modulation of Inflammation and Lung Cancer Risk$288,898
P50 · FY2013 · CA · contact PI
Vitamin D3 Modulation of Inflammation and Lung Cancer Risk$286,475
P50 · FY2012 · CA · contact PI